Ticker >

Venus Remedies share price

Venus Remedies Ltd.

NSE: VENUSREM BSE: 526953 SECTOR: Pharmaceuticals & Drugs  27k   67   4

299.00
+1.85 (0.62%)
NSE: Today, 11:34 AM

Price Summary

Today's High

₹ 302.7

Today's Low

₹ 295.3

52 Week High

₹ 430

52 Week Low

₹ 222

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

399.67 Cr.

Enterprise Value

385.78 Cr.

No. of Shares

1.34 Cr.

P/E

15.66

P/B

0.81

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  370.9

CASH

52.57 Cr.

DEBT

38.68 Cr.

Promoter Holding

41.76 %

EPS (TTM)

₹  19.09

Sales Growth

-6.77%

ROE

6.25 %

ROCE

8.03%

Profit Growth

-40.87 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-6.77%
3 Year18.85%
5 Year8.65%

Profit Growth

1 Year-40.87%
3 Year76.74%
5 Year25.31%

ROE%

1 Year6.25%
3 Year11.02%
5 Year4.6%

ROCE %

1 Year8.03%
3 Year9.46%
5 Year5.81%

Debt/Equity

0.0809

Price to Cash Flow

14.25

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

3.33162066228556

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 41.76 0
Dec 2023 41.76 0
Sep 2023 41.76 0
Jun 2023 41.76 0
Mar 2023 41.76 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 76.7385279065082% for the Past 3 years.
  • The company has shown a good revenue growth of 18.8542408445053% for the Past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 67.1498279130947 days.
  • Company has a healthy liquidity position with current ratio of 4.38035855828086.
  • The company has a good cash flow management; CFO/PAT stands at 3.33162066228556.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.81553287047677.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 109.45 148.53 98.63 170.19 131.23
Total Expenditure 102.37 127.5 85.16 157.06 118.23
Operating Profit 7.08 21.03 13.47 13.13 13
Other Income 3.75 3.24 2.06 2.93 2.42
Interest 0 0 0 0 0
Depreciation 6.97 8.06 7.32 6.21 6.3
Exceptional Items 0 0 0 0 0
Profit Before Tax 3.86 16.21 8.21 9.85 9.12
Tax 1.25 8.67 3.87 4.4 0.93
Profit After Tax 2.61 7.54 4.34 5.45 8.19
Adjusted EPS (Rs) 1.95 5.64 3.25 4.08 6.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 301.84 320.23 514.62 576.71 537.66
Total Expenditure 267.55 277.16 467.76 507.89 476.14
Operating Profit 34.29 43.07 46.86 68.82 61.53
Other Income 4.51 3.58 17.76 8.43 10.17
Interest 25.15 13.05 12.73 0 0
Depreciation 32.95 31.05 34.28 32.58 31.37
Exceptional Items -8.96 -8.81 23.44 0 0
Profit Before Tax -28.26 -6.26 41.06 44.67 40.33
Tax -1.15 1.96 -13.21 -4.32 11.36
Net Profit -27.11 -8.23 54.27 48.99 28.96
Adjusted EPS (Rs.) -21.97 -6.67 43.97 36.65 21.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 12.34 12.34 12.34 13.37 13.37
Total Reserves 328.61 319.91 387.84 436.05 464.68
Borrowings 116.08 72.26 47.52 38.68 38.68
Other N/C liabilities 20.66 23.77 11.29 7.27 19.49
Current liabilities 254.46 215.98 87.82 82.61 72.67
Total Liabilities 732.16 644.27 546.81 577.98 608.89
Assets
Net Block 346.89 271.47 244.2 224.67 199.68
Capital WIP 64.76 24.63 25.11 25.23 26.1
Intangible WIP 0 0 0 0 0
Investments 0.14 0.14 0.14 0.14 0.14
Loans & Advances 66.78 64.08 62.34 61.96 62.55
Other N/C Assets 0 0 1.29 1.57 2.11
Current Assets 253.59 283.94 213.74 264.41 318.32
Total Assets 732.16 644.27 546.81 577.98 608.89
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -19.3 2.55 17.62 44.67 40.33
Adjustment 59.2 40.39 21.59 24.83 22.25
Changes in Assets & Liabilities 3.75 20.37 69.69 -28.5 -34.53
Tax Paid 0 0 0 0 0
Operating Cash Flow 43.65 77.75 132.34 41 28.05
Investing Cash Flow -11.27 -4.64 55.98 -16.75 -50.81
Financing Cash Flow -34.74 -72.35 -161.88 -9.13 0
Net Cash Flow -2.36 0.76 26.45 15.12 -22.76

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 41.76 41.76 41.76 41.76 41.76
manu chaudhary 11.73 11.73 11.73 11.73 11.73
pawan chaudhary - - - - 12.82
sunev pharma solutions li... 17.21 17.21 17.21 17.21 17.21
pawan chaudhary 12.82 12.82 12.82 12.82 -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 58.24 58.24 58.24 58.24 58.24
acadian emerging markets ... - - - - 1.05
investor education and pr... - 1.00 - 1.00 1.00
k.b.shekar 1.93 - - 1.92 1.97
llp 0.14 0.20 - 0.27 0.17
mc jain infoservices priv... - - - - 1.28
pradeep kumar jain 1.11 - 1.21 - 1.19
investor education and pr... 1.01 - 1.00 - -
k.b. shekhar - 1.93 1.93 - -
pradeep kumar jain - 1.21 - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Venus Remedies informs about disclosure 1 Apr 2024, 12:58PM Venus Remedies gets marketing authorisations from Ukraine for three cancer drugs18 Mar 2024, 4:47PM Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine9 Mar 2024, 3:39PM Venus Remedies awarded first incentive of Rs 7.50 crore under PLI scheme6 Mar 2024, 10:30AM Venus Remedies informs about press release6 Mar 2024, 9:33AM Venus Remedies - Quaterly Results14 Feb 2024, 8:01PM Venus Remedies - Quaterly Results14 Feb 2024, 8:01PM Venus Remedies secures marketing authorizations for Docetaxel, Gemcitabine in Europe12 Jan 2024, 12:30PM Venus Remedies secures marketing authorizations for Docetaxel in Israel, Cytarabine in Colombia21 Dec 2023, 3:13PM Venus Remedies’ R3SET forays into wellness arena20 Dec 2023, 2:10PM Venus Remedies informs about press release20 Dec 2023, 12:56PM Venus Remedies informs about disclosure 5 Dec 2023, 12:16PM Venus Remedies gets market authorizations for Enoxaparin in Azerbaijan5 Dec 2023, 11:09AM Venus Remedies informs about press release1 Dec 2023, 2:06PM Venus Remedies informs about unaudited financial results 25 Nov 2023, 3:19PM Venus Remedies informs about press release6 Nov 2023, 10:23AM Venus Remedies secures ‘Three Star Export House’ certificate from Government of India6 Nov 2023, 9:49AM Venus Remedies informs about press release1 Nov 2023, 10:45AM Venus Remedies wins FICCI Healthcare Award 20231 Nov 2023, 9:52AM Venus Remedies achieves market authorization for Bleomycin in United Kingdom 26 Oct 2023, 12:07PM Venus Remedies informs about press release26 Oct 2023, 10:38AM Venus Remedies informs about press release 20 Oct 2023, 11:24AM Venus Remedies informs about press release16 Oct 2023, 10:25AM Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines16 Oct 2023, 9:49AM Venus Remedies expands global reach with launch of Elores in Ecuador 12 Oct 2023, 3:39PM Venus Remedies informs about details of loss of certificate 26 Sep 2023, 4:49PM Venus Remedies informs about loss of share certificate23 Sep 2023, 4:31PM Venus Remedies secures marketing authorization from Serbia for gemcitabine and docetaxel20 Sep 2023, 11:29AM Venus Remedies informs about press release20 Sep 2023, 11:19AM Venus Remedies registers with DSIR to avail custom duty exemption14 Sep 2023, 2:10PM Venus Remedies gets marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes28 Aug 2023, 2:09PM Venus Remedies launches R&D drug Elores in Oman17 Aug 2023, 12:41PM Venus Remedies - Quaterly Results14 Aug 2023, 7:29PM Venus Remedies informs about press release31 Jul 2023, 12:21PM Venus Remedies gets marketing approvals for oncology products across 76 countries31 Jul 2023, 11:53AM Venus Remedies informs about update on trading restriction of company shares 24 Jul 2023, 5:06PM Venus Remedies informs about press release 24 Jul 2023, 12:13PM Venus Remedies informs about certificate13 Jul 2023, 12:10PM Venus Remedies gets marketing approval from 4 countries for chemotherapy drugs5 Jul 2023, 6:18PM Venus Remedies informs about board meeting5 Jul 2023, 5:25PM Venus Remedies informs about press release 5 Jul 2023, 2:25PM Venus Remedies informs about press release22 Jun 2023, 3:16PM Venus Remedies informs about press release22 Jun 2023, 2:17PM Venus Remedies gets marketing authorisation from Spain for meropenem22 Jun 2023, 2:10PM Venus Remedies gets GMP certification from Ukraine7 Jun 2023, 12:17PM Venus Remedies informs about press release7 Jun 2023, 11:30AM Venus Remedies informs about press release1 Jun 2023, 3:04PM Venus Remedies secures marketing authorization for chemotherapy drug 'Docetaxel'1 Jun 2023, 12:58PM Venus Remedies informs about newspaper publication31 May 2023, 3:32PM Venus Remedies - Quaterly Results29 May 2023, 10:54PM

Venus Remedies Stock Price Analysis and Quick Research Report. Is Venus Remedies an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Venus Remedies and its performance over the period of time. Venus Remedies stock price today is Rs 299.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Venus Remedies cash from the operating activity was Rs 28.0548 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Venus Remedies has a Debt to Equity ratio of 0.0809 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Venus Remedies , the EPS growth was -40.8727494992823 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Venus Remedies has OPM of 11.4432136627126 % which is a bad sign for profitability.
     
  • ROE: Venus Remedies have a poor ROE of 6.24595602898192 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Venus Remedies is Rs 299. One can use valuation calculators of ticker to know if Venus Remedies share price is undervalued or overvalued.
Last Updated on:
Brief about Venus Remedies
X